Pet care shines as growth driver

Boehringer Ingelheim reported strong financial results for 2025, with net revenue rising 7.3% to €27.8 bn. According to a press release, the Human Pharma division led growth, generating €22.7 bn, up 7.4%. Key products performed robustly: Jardiance, which treats diabetes, heart failure and chronic kidney disease, climbed 8.7% to €8.8 bn, whilst Ofev, used for pulmonary fibrosis and progressive lung disease, grew 5.4% to €3.8 bn. Research and development investment reached a record €6.4 bn, representing 22.9% of total revenue. The company also successfully launched two new medicines ‒ Hernexeos, an oral treatment for lung cancer, and Jascayd, the first new idiopathic pulmonary fibrosis therapy in over a decade ‒ in the United States and China.

Boehringer Ingelheim's Animal Health division demonstrated strong resilience in 2025, with revenue climbing 6.5% to €4.9 bn. Pet care was a standout driver, with antiparasitic treatments and therapeutics for companion animals performing particularly well. NexGard, the industry's best-selling antiparasitic brand, grew 8.5% to €1.4 bn.

The division worked closely with farmers, veterinarians and authorities to combat notifiable animal diseases, including avian influenza, foot-and-mouth disease and bluetongue virus. Boehringer received EU market authorisation under exceptional circumstances, the release says, as two new poultry vaccines were introduced.

For 2026, Boehringer Ingelheim aims to build on recent momentum through continued advances across both its Animal Health and Human Pharma pipelines, with key milestones anticipated in cardiovascular, renal and metabolic diseases, oncology, and eye health.